Insulet (PODD): Continues Beating Despite Concerns - Jefferies

Jefferies analyst, Raj Denhoy, reiterated his Buy rating on shares of Insulet Corporation (NASDAQ: PODD) after the company posted a very strong quarter despite concerns that the pump market is being roiled by competition, Revenue in the US was up +18%, OUS was up a whopping +63%, and
drug delivery was +12%. The US installed base grew +15%, OUS +60%, and
overall global +30%.

The analyst believes that PODD is making progress on a host of programs that should keep sales and margins trending higher but the story is not without its risks, and the analyst cut his price target to $48 from $53.

For an analyst ratings summary and ratings history on Insulet Corporation click here. For more ratings news on Insulet Corporation click here.

Shares of Insulet Corporation closed at $41.37 yesterday.

You May Also Be Interested In

• Lionsgate Studios Corp (LION) PT Raised to $17 at Benchmark on Long-Term Business Dynamics
• New Street Research Starts SpaceX (SPCX) at $165 Price Target
• Datadog (DDOG) PT Raised to $260 at Benchmark as Checks Reveal Positive Feedback